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Purpose of the study
To evaluate cART efficacy, number of regimens and resist-
ance development in vertically HIV-infected children
treated since infancy.
Methods
27 children vertically infected with HIV. In 6/27 children
treatment was started before HAART era. In 11/27 patients
cART regimen was based on baseline resistance reports.
Additionally, in eight children resistance tests were per-
formed before therapy changing. (Table 1.)
Summary of Results
6/27 (22%) children have been receiving their first regi-
men (the length of treatment: 10 months – 4.5 years). 21/
27 (78%) patients have changed their therapies, including
12/21 (57%) with treatment failure.
Conclusions
cART in vertically HIV-infected children treated since
infancy is effective. Most of the patients had to change
their regimens because of treatment failure or adverse
events. Multidrug resistance (double or triple class)
appeared in 15% of patients.
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Table 1: cART efficacy
ART before HAART era 
(before 1998)
Initial cART started without 
resistance testing
Initial cART based on 
resistance reports
No.of children 6 10 11
Current age 10–14 yr (mean 12 yr) 10 mo – 10 yr (mean 6 yr) 2–7 yr (mean 4, 5 yr)
The first regimen NRTI cART cART
No. of cART regimens 2–3 1–5 1–3
No. of children receiving their first 
regimen currently
0 3 3
No. of children with VL<50 c/ml at 
evaluation
6 10 9
No. of patients with resistance 
testing before changing of ART
2 4 2
Single class resistance 
development
2 children (NRTI) 1 child (PI) 1 child (NRTI)
Double class resistance 
development
1 child (PI+NNRTI)
Triple class resistance 
development
2 children 1 child
